Multimodal Intervention for GGT Reduction in Alcohol Use Disorder (GGT-AUD)

Alcohol Use Disorder (AUD) is commonly associated with liver dysfunction, which can be reflected by elevated levels of gamma-glutamyl transferase (GGT). Monitoring changes in GGT levels may provide useful information about liver status and response to interventions aimed at reducing alcohol-related harm.

This study evaluates a multimodal approach that combines nutraceutical support with psychological intervention in individuals with AUD and elevated GGT levels. The rationale for this combined approach is to address both the biological and behavioral components of alcohol use.

Participants were included based on the presence of Alcohol Use Disorder and elevated baseline GGT levels. For analysis purposes, participants were stratified according to baseline GGT values (55-99 U/L and ≥100 U/L).

The study focuses on assessing changes in GGT levels over time following the intervention. Additional analyses explore variations in response based on baseline GGT levels.

This study aims to contribute to the understanding of integrated approaches for improving liver-related biomarkers in individuals with Alcohol Use Disorder.

Inclusion criteria

• Adults aged 18 years or older
• Diagnosis of Alcohol Use Disorder
• Elevated baseline gamma-glutamyl transferase (GGT) levels
• Ability to provide informed consent

Exclusion criteria

• Severe liver disease (e.g., cirrhosis or hepatic failure)
• Severe psychiatric disorders interfering with participation
• Current participation in another clinical study
• Incomplete clinical or laboratory data